#cabotegravir

[gwydionmisha]

Coming Soon: Long-Lasting, Injectable PrEP

Research shows long-acting, injectable cabotegravir is more effective at keeping HIV at bay than a daily pill.

[redebcn]

Prevenção Injetável Contra HIV: Cabotegravir Próximo do SUS

O Sistema Único de Saúde (SUS) poderá disponibilizar uma nova modalidade de profilaxia pré-exposição (PrEP) para prevenção do HIV ainda neste ano. Trata-se do medicamento cabotegravir, administrado por injeção a cada dois meses, que inibe a replicação viral de forma prolongada. Processo de Incorporação e Negociações O Ministério da Saúde encaminhará o pedido de inclusão à Comissão Nacional de…

[realjdobypr]

ViiV Advances Ultra Long-Acting HIV Care at CROI

At this year’s Conference on Retroviruses and Opportunistic Infections in Denver, ViiV Healthcare outlined a future of HIV care increasingly defined by longer dosing intervals, expanded prevention options and data-driven personalization. The global HIV specialist company, majority owned by GSK with Pfizer and Shionogi as shareholders, presented new clinical and real-world findings spanning its established portfolio and next-generation pipeline. Central to the discussion was the evolution toward ultra-long-acting treatment strategies designed to reduce dosing frequency while maintaining viral suppression and prevention efficacy. Jean van Wyk, MBChB, MFPM, Chief Medical Officer at ViiV Healthcare, said, “We are making major advances towards new ultra-long-acting regimens that build on ViiV’s legacy of integrase inhibitors, including pipeline assets such as VH184 that have the potential to extend dosing intervals to four months or longer, beyond what is available today for HIV treatment. Listening to the needs of the HIV community shapes our research and development, and the breadth of clinical and real-world data we are presenting at CROI 2026 reflects our commitment to delivering long-acting therapies that people impacted by HIV need and want.” Spotlight on a Third-Generation Integrase Inhibitor Among the most closely watched updates was first-in-human data for long-acting formulations of VH184, described as the first third-generation integrase strand transfer inhibitor. Early pharmacokinetic findings from the ongoing Phase I study offered insight into how injectable versions of the compound may support ultra-long-acting regimens in the future. Additional laboratory analyses evaluating VH184’s resistance profile compared with bictegravir further positioned the compound as a potential next step in integrase inhibitor innovation. Complementing this work were early data on VH499, an investigational capsid inhibitor. Interim findings examined dosing feasibility and exposure-response relationships, contributing to the broader ultra-long-acting development strategy. You can read the official report on its dedicated page. Exploring Four-Month Dosing Horizons ViiV also shared interim results from the Phase IIb EMBRACE study evaluating lotivibart, an investigational broadly neutralizing antibody administered every four months, in combination with monthly long-acting cabotegravir. Twelve-month data examined sustained viral suppression and safety, offering early evidence supporting longer dosing intervals. Parallel research from the Phase I CAB ULA 012 study explored dose selection for ultra-long-acting cabotegravir in prevention, with the goal of extending pre-exposure prophylaxis administration to every four months. Together, these studies reflect a shift toward treatment and prevention regimens that may reduce the frequency of clinic visits while maintaining adherence and effectiveness. Real-World Evidence Across Established Therapies In addition to pipeline advancements, ViiV presented new analyses supporting its established long-acting and two-drug regimens. Late-breaking data from the Phase IIIb VOLITION study provided Month 11 outcomes for treatment-naïve adults who switched to long-acting cabotegravir plus rilpivirine after achieving viral suppression on once-daily dolutegravir and lamivudine. Real-world analyses from the OPERA cohort examined virologic outcomes across body mass index categories and evaluated long-term results for individuals initiating long-acting therapy with varying baseline viral loads. For prevention, updated OPERA findings assessed the effectiveness of long-acting cabotegravir for PrEP over three years in routine care settings. Additional data focused on uptake, coverage compared with oral PrEP and twelve-month real-world effectiveness among Black women, a population disproportionately impacted by HIV. Strengthening Dolutegravir-Based Treatment Beyond injectable innovation, ViiV presented new data reinforcing dolutegravir-based regimens across diverse populations.

A meta-analysis compared two-drug dolutegravir and lamivudine therapy with three-drug regimens in treatment-naïve individuals with high baseline viral loads and low CD4 counts. Findings from the PASO DOBLE trial provided insight into metabolic outcomes, including steatotic liver disease and adipose tissue changes at 96 weeks. The SUNGURA study contributed additional safety and efficacy data among adults aged 60 and older who switched regimens, reflecting a growing emphasis on aging populations living with HIV. Expanding Pediatric Options Several presentations addressed pediatric HIV treatment. Week 96 results from adolescent studies evaluating long-acting cabotegravir plus rilpivirine highlighted sustained suppression in younger age groups. Additional safety and pharmacokinetic data in children weighing less than 20 kilograms offered insight into long-acting treatment strategies for smaller pediatric populations. Separate findings from Southern Africa described viral suppression rates among children aged five and younger receiving dolutegravir-based regimens, underscoring the medication’s role in pediatric care. A Broader Wellness Perspective The growing emphasis on ultra-long-acting treatment reflects more than pharmacological progress. For many people living with HIV, fewer dosing intervals can translate into reduced stigma, improved adherence and greater autonomy in daily life. As prevention strategies evolve alongside treatment innovations, ViiV’s research agenda signals a dual focus: maintaining viral suppression for those living with HIV while expanding preventive tools for those at risk. With data spanning laboratory research, controlled clinical trials and real-world outcomes, the presentations at CROI 2026 underscore a central theme in modern HIV care: long-acting science is redefining how treatment and prevention integrate into everyday wellness. For full prescribing information on specific medicines referenced, consult official product documentation and healthcare providers.

[medicomunicare]

Long-lasting PrEParations come towards patients' AIDs: daily pills could not be the only hope-tion

In 2021, federal regulators approved the first long-acting antiretroviral (LA-ART) injectable, which is a combination of long-acting cabotegravir and rilpivirine. But they only approved it for HIV patients who already had their infections under control with pills. Researchers at University of San Francisco wanted to see if it would work for patients who could not control their infections with…

[scienza-magia]

Più mesi di protezione da HIV con il lenacapavir

Il farmaco antiHIV è la scoperta dell'anno, secondo Science. Si chiama lenacapavir ed è in grado di prevenire l'infezione dal virus. Si chiama lenacapavir, è un farmaco innovativo in grado di prevenire l'infezione da virus dell'immunodeficienza umana (HIV), garantendo sei mesi di protezione dall'agente patogeno. Nominato scoperta dell'anno 2024 dalla rivista Science, questo importante risultato è emerso dall'indagine CAPELLA, che ha documentato un importante successo nei pazienti a rischio di contrarre l'infezione. Il premio riconosce anche il lavoro correlato che circonda l'acquisizione di una nuova comprensione della struttura e della funzione della proteina capside dell'HIV. Nonostante decenni di progressi nel contrastare e prevenire la diffusione, il virus dell'immunodeficienza umana continua a infettare più di un milione di persone ogni anno, e non è ancora disponibile un vaccino efficace. Il lenacapavir potrebbe colmare queste carenze. Secondo gli studi clinici, in effetti, il farmaco, disponibile come iniezione, fornisce sei mesi di protezione dal contagio.

Ospedale pediatrico bambin gesù progetto EpIIcal hiv aids L'indagine ha rivelato che il medicinale garantisce un'efficacia del 100 per cento nelle adolescenti africane e del 99,9 per cento nella popolazione di genere diverso in tutti i continenti. Il lenacapavir deriva da una ricerca rivoluzionaria sulla proteina capside dell'HIV, che protegge il materiale genetico del virus. Indurendo questa proteina, il farmaco blocca le fasi chiave della replicazione virale. Questo meccanismo di targeting del capside, un tempo ritenuto impraticabile, potrebbe ispirare trattamenti per altre malattie virali. Inizialmente sviluppato come terapia di salvataggio per pazienti resistenti ad altri farmaci, la forma iniettabile a lunga durata del lenacapavir lo rende un punto di svolta nella prevenzione dell'HIV e della sindrome da immunodeficienza acquisita (AIDS). Il farmaco supera i problemi di aderenza riscontrati con la profilassi orale pre-esposizione giornaliera (PrEP) e le iniezioni bimestrali come il cabotegravir, in particolare per le popolazioni che affrontano stigma e difficolta' di accesso. Tuttavia, il suo potenziale di ridurre drasticamente le infezioni nelle popolazioni ad alto rischio ne sottolinea l'importanza. In combinazione con i precedenti progressi biomedici, il lenacapavir, sottolineano gli scienziati, rappresenta un passo fondamentale verso la riduzione dell'HIV/AIDS come crisi sanitaria globale. Read the full article